Results 11 to 20 of about 103,602 (308)

Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins

Blood Cancer Discovery, 2021
Abstract The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations.
Yasen Maimaitiyiming, Qian Qian Wang, Chang Yang, Yasumitsu Ogra, Yinjun Lou, Clayton A. Smith, Liaqat Hussain, Yi Ming Shao, Jiebo Lin, Jinfeng Liu, Lingfang Wang, Yong Zhu, Haiyan Lou, Yuan Huang, Xiaoxia Li, Kao-Jung Chang, Hao Chen, Hongyan Li, Ying Huang, Eric Tse, Jie Sun, Na Bu, Shih-Hwa Chiou, Yan Fang Zhang, Hao Ying Hua, Li Ya Ma, Ping Huang, Ming Hua Ge, Feng-Lin Cao, Xiaodong Cheng, Hongzhe Sun, Jin Zhou, Vasilis Vasliou, Pengfei Xu, Jie Jin, Mikael Bjorklund, Hong-Hu Zhu, Chih-Hung Hsu, Hua Naranmandura   +38 more
openaire   +2 more sources

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

International Journal of Molecular Sciences, 2023
CD74 is a type II cell surface receptor found to be highly expressed in several hematological and solid cancers, due to its ability to activate pathways associated with tumor cell survival and proliferation. Over the past 16 years, CD74 is emerging as a commonly detected fusion partner in multiple oncogenic fusion proteins.
Jasmine Vargas, Georgios Pantouris
openaire   +2 more sources

The fusion partner specifies the oncogenic potential of NUP98 fusion proteins [PDF]

Leukemia Research, 2013
NUP98 is among the most promiscuously translocated genes in hematological diseases. Among the 28 known fusion partners, there are two categories: homeobox genes and non-homeobox genes. The homeobox fusion partners are well-studied in animal models, resulting in HoxA cluster overexpression and hematological disease.
Saw, J, Curtis, DJ, Hussey, DJ, Dobrovic, A, Aplan, PD, Slape, CI   +5 more
openaire   +5 more sources

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins [PDF]

Proceedings of the National Academy of Sciences, 2013
Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that ROS1 inhibitors are likely to be effective molecularly targeted therapies in these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib to treat ROS1 fusion-harboring non–small-cell lung cancer ...
Monika A, Davare, Anna, Saborowski, Christopher A, Eide, Cristina, Tognon, Rebecca L, Smith, Johannes, Elferich, Anupriya, Agarwal, Jeffrey W, Tyner, Ujwal P, Shinde, Scott W, Lowe, Brian J, Druker   +10 more
openaire   +2 more sources

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium [PDF]

Oncogene, 2018
Structural rearrangements of the genome can drive lung tumorigenesis through the generation of fusion genes with oncogenic properties. Advanced genomic approaches have identified the presence of a genetic fusion between fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil 3 (TACC3) in non-small cell lung cancer (NSCLC ...
Sarah A. Best, Cassandra R. Harapas, Ariena Kersbergen, Vivek Rathi, Marie-Liesse Asselin-Labat, Kate D. Sutherland   +5 more
openaire   +3 more sources

Detecting and targetting oncogenic fusion proteins in the genomic era [PDF]

Biology of the Cell, 2015
The advent of widespread cancer genome sequencing has accelerated our understanding of the molecular aberrations underlying malignant disease at an unprecedented rate. Coupling the large number of bioinformatic methods developed to locate genomic breakpoints with increased sequence read length and a deeper understanding of coding region function has ...
Monika A, Davare, Cristina E, Tognon
openaire   +2 more sources

Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein [PDF]

Oncogene, 2003
In Ewing's sarcoma family tumors, the ets transcription factor gene FLI1 is rearranged with one EWS allele resulting in coexpression of germline EWS and chimeric EWS-FLI1 proteins. Here, we investigated the potential of germline EWS, FLI1 and EWS-FLI1 to oligomerize. In two functional in vivo tests, fluorescence resonance energy transfer (FRET) and the
Laura, Spahn, Christine, Siligan, Radostina, Bachmaier, Johannes A, Schmid, Dave N T, Aryee, Heinrich, Kovar   +5 more
openaire   +2 more sources

Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors [PDF]

Translational Oncology, 2020
Chromosomal translocations such as t(10;12)(q26,q12) are associated with intrahepatic cholangiocarcinoma, a universally fatal category of liver cancer. This translocation creates the oncogenic fusion protein of Fibroblast Growth Factor Receptor 2 joined to Periphilin 1.
Li, Fangda, Meyer, April N, Peiris, Malalage N, Nelson, Katelyn N, Donoghue, Daniel J   +4 more
openaire   +4 more sources

Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing [PDF]

Proceedings of the National Academy of Sciences, 2007
MicroRNAs (miRNAs) are noncoding small RNA of ≈22 bases, which suppress expression of target genes through translational block or degradation of a target's transcript. Recent studies uncovered specific miRNA expression profiles in human malignancies.
Tatsuya Nakamura, Eli Canaani, CROCE, Carlo Maria   +2 more
openaire   +3 more sources

MTAP-ANRIL gene fusion promotes melanoma epithelial-mesenchymal transition-like process by activating the JNK and p38 signaling pathways

Scientific Reports, 2023
Gene fusions caused by cytogenetic aberrations play important roles in the initiation and progression of cancers. The recurrent MTAP-ANRIL fusion gene was reported to have a frequency of greater than 7% in melanoma in our previous study.
Zhuoying Lin, Yu Lei, Mingyao Wen, Qin He, Dean Tian, Huaping Xie   +5 more
doaj   +1 more source